Sana Biotechnology Cash Flow Statement
NASDAQ: SANAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
2.790.00 (0.00%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Sana Biotechnology free cash flow
In fiscal 2025, Sana Biotechnology generated -$143.8 million of operating cash flow and spent $938,000 on capital expenditures. That left free cash flow of -$144.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Sana Biotechnology cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Net Income | -244.17M | -266.76M | -283.25M | -269.48M | -355.93M | -285.31M | -130.78M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| Depreciation & Amortization | 12.80M | 15.50M | 17.50M | 15.60M | 11.10M | 5.92M | 1.83M |
| Stock-Based Compensation | 25.46M | 37.68M | 35.53M | 38.34M | 22.36M | 5.83M | 1.50M |
| Change in Working Capital | -2.38M | -2.14M | 9.17M | -4.93M | -1.13M | 546.00K | -4.72M |
| Operating Cash Flow | -143.83M | -223.15M | -253.58M | -290.05M | -251.05M | -137.98M | -85.52M |
| Capital Expenditures | -938.00K | -33.43M | -20.03M | -20.88M | -29.86M | -23.87M | -26.12M |
| Investing Cash Flow | -40.24M | 17.45M | 172.01M | 210.56M | -245.80M | -252.56M | -87.86M |
| Financing Cash Flow | 128.73M | 199.75M | 31.65M | 4.91M | 631.75M | 435.69M | 223.74M |
| Net Change in Cash | -55.33M | -5.95M | -49.92M | -74.58M | 134.90M | 45.14M | 50.36M |
| Free Cash Flow | -144.77M | -256.58M | -273.61M | -310.93M | -280.92M | -161.85M | -111.64M |
This table shows 7 annual periods of Sana Biotechnology's cash flow statement, from FY 2025 back to FY 2019, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SANA's reporting calendar. What is a cash flow statement?